HALB Archives - Page 5 of 6 - Halberd Corporation

Nov 12 2020

Halberd Corporation Reveals Patent-Pending Fluorescent Antibody’s Wide Role in Covid-19 Detection & Treatment

By Admin|2020-11-11T20:25:36-05:00November 12th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, November 12, 2020 – Halberd Corporation (OTC PINK: "HALB") today disclosed information on their patent-pending fluorescent anti-Spike protein monoclonal antibodies against Covid-19 developed in conjunction with Dr. Qiang (Shawn) Chen of Arizona State University. The salient feature of Halberd’s new class of antibody is that it fluoresces in the presence of Covid-19 ...

Oct 27 2020

Halberd Corp. Retains Prestigious Patent Law Firm on Covid-19-Related and Other Disease Technologies

By Admin|2020-10-26T18:49:33-04:00October 27th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, October 27, 2020 – Halberd Corporation (OTC PINK: "HALB") has retained the services of a prestigious Pittsburgh, PA law firm, Ference & Associates, to handle its intellectual property matters. The initial application focuses on patenting Halberd’s base Covid-19 antibody as well as an entire new class of antibody conjugate. The primary attorney ...

Oct 26 2020

ICYMI — Halberd Corporation Discusses The Development of New Class of COVID-19 Antibody with The Stock Day Podcast

By Admin|2020-10-25T21:54:06-04:00October 26th, 2020|Featured, Investor News, News|0 Comments

In Case You Missed It Phoenix, Arizona–(Newsfile Corp. – October 22, 2020) – The Stock Day Podcast welcomed Halberd Corporation (OTC Pink: HALB) (“the Company”), a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. CEO of the Company, Bill Hartman, joined Stock Day host Everett Jolly. ...

Oct 19 2020

Arizona State University/Halberd Initiate Patent Application for Unique New Engineered Class of Covid-19 Antibody

By Admin|2020-10-19T12:43:39-04:00October 19th, 2020|Featured, Investor News, News|0 Comments

Updated 12:30PM Jackson Center, PA, October 19, 2020 – Halberd Corporation (OTC PINK: "HALB") today announced the creation of a new class of anti-Spike protein monoclonal antibodies against Covid-19. The discovery is the result of Halberd’s research in conjunction with Arizona State University’s Dr. Qiang “Shawn” Chen, utilizing Halberd’s intellectual property created by Mitchel S. ...

Oct 13 2020

Arizona State University/Halberd Develop Antibody Against Covid-19

By Admin|2020-10-12T20:32:43-04:00October 13th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, October 13, 2020 – Halberd Corporation (OTC PINK: "HALB") reported that Arizona State University researchers, utilizing the intellectual property of Halberd Corporation, have successfully generated an anti-Spike protein monoclonal antibody against Covid-19. The Spike Protein is a main component of the Covid-19 virus, and is a crucial component in its ability to replicate. ...

Oct 8 2020

Halberd Corporation CEO Update Letter – October, 2020

By Admin|2020-10-07T19:53:21-04:00October 8th, 2020|Featured, Investor News|0 Comments

Greetings From The CEO And Staff At Halberd Corporation! (OTC-PINK: HALB) This initial CEO Letter reflects a summary of major accomplishments since I began my tenure at Halberd Corporation. Going forward, I intend to provide update letters to our shareholders and the public on a quarterly basis. A LOOK BACK Since I began at Halberd ...

Sep 28 2020

Arizona State University/Halberd Pursue Nasal Spray As Covid-19 Preventative/Treatment Based On Children’s Natural Immunity

By Admin|2020-09-27T19:42:54-04:00September 28th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 28, 2020 – Children are far less susceptible than adults to the Coronavirus (1, 2). Halberd Corporation’s (OTC PINK: "HALB") scientists have determined the reason may be that adults have far more Angiotensin-Converting Enzyme 2 (ACE2) receptors in nasal membrane epithelial cells. ACE2 (3) is a membrane protein expressed in many ...

Sep 24 2020

Arizona State University/Halberd Corp. Covid-19 R&D Program Rapid Diagnostic Test / Treatment

By Admin|2020-09-23T20:35:03-04:00September 24th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 24, 2020 – Halberd Corporation (OTC PINK: "HALB") clarifies next steps in their unique research with Arizona State University. Halberd directed their research program to focus on that element of Covid-19 which makes the disease most contagious -- the spike antigen. ASU investigators have projected the production of the coronavirus spike ...

Sep 21 2020

Arizona State University/Halberd Corp. Covid-19 Research Program Progress – Successful Covid Spike Protein Disease Antigen Re-Creation!

By Admin|2020-09-20T20:34:28-04:00September 21st, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 21, 2020 – Halberd Corporation (OTC PINK: "HALB") released a progress update on the research being conducted in conjunction with Arizona State University researchers. Dr. Qiang Chen, ASU’s lead researcher, reports the successful re-creation of the coronavirus spike protein disease antigen in laboratory research. With this breakthrough, Dr. Chen’s team will ...

Sep 17 2020

Arizona State University/Halberd Corp. Outline Partnership 2nd Stage Goals of $1.4 M Covid-19 Program

By Admin|2020-09-17T08:26:31-04:00September 17th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 17, 2020 – Halberd Corporation (OTC PINK: "HALB") today outlined the specifics of the second stage goals of the $1.4 Million seven-phase research project with Arizona State University. The second stage of the research involves an investigation of a method using dialysis, or a variant of dialysis, to remove the fluorescent ...

Previous 456 Next